Contact & Investor Inquiry
We are actively seeking investment partners, clinical collaborators, and research institutions to advance the development of the White Blood Cell Environmental Toxin Assessment into a validated commercial diagnostic test.
Why Partner With Us
This provisional patent application represents a first-in-class diagnostic methodology that addresses a fundamental gap in modern toxicology: measuring the intracellular toxin burden in immune cells, where toxins actually cause disease.
Patent pending — provisional application filed with the USPTO
Multi-modal method combining HRMS + EIS — novel combination with no direct prior art
Covers 31+ toxins across 7 classes including heavy metals, mycotoxins, PFAS, and agricultural chemicals
Human and veterinary applications — two distinct commercial markets
Addresses a $4B+ and growing environmental diagnostics market